238 related articles for article (PubMed ID: 37261361)
21. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
22. Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer.
Gaui MFD; Amendola LC; Quintella DC; Canedo N; Bonomo A
Rev Assoc Med Bras (1992); 2023; 69(9):e20230276. PubMed ID: 37729362
[TBL] [Abstract][Full Text] [Related]
23. [Systemic therapy and hyperthermia for locally advanced soft tissue sarcoma].
Lindner LH; Angele M; Dürr HR; Rauch J; Bruns C
Chirurg; 2014 May; 85(5):398-403. PubMed ID: 24740176
[TBL] [Abstract][Full Text] [Related]
24. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.
Xing X; Shi J; Jia Y; Dou Y; Li Z; Dong B; Guo T; Cheng X; Li X; Du H; Hu Y; Jia S; Zhang J; Li Z; Ji J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361730
[TBL] [Abstract][Full Text] [Related]
25. Changes in the tumor immune microenvironment in resected recurrent soft tissue sarcomas.
Zheng B; Wang J; Cai W; Lao I; Shi Y; Luo X; Yan W
Ann Transl Med; 2019 Aug; 7(16):387. PubMed ID: 31555701
[TBL] [Abstract][Full Text] [Related]
26. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
27. [Correlation between Immune Microenvironment Features and EGFR Mutation Status
in Lung Adenocarcinoma].
Zhu H; Chen P; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Yuan F; Yu X; Sun Q; Ji J; Wang S; Liu T; Xu L
Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):204-216. PubMed ID: 37035883
[TBL] [Abstract][Full Text] [Related]
28. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
29. Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas.
Judge SJ; Bloomstein JD; Sholevar CJ; Darrow MA; Stoffel KM; Vick LV; Dunai C; Cruz SM; Razmara AM; Monjazeb AM; Rebhun RB; Murphy WJ; Canter RJ
Front Immunol; 2022; 13():893177. PubMed ID: 35874727
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.
Mullen JT; Hornicek FJ; Harmon DC; Raskin KA; Chen YL; Szymonifka J; Yeap BY; Choy E; DeLaney TF; Nielsen GP
Cancer; 2014 Dec; 120(23):3676-82. PubMed ID: 25081640
[TBL] [Abstract][Full Text] [Related]
31. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy plus radiation versus chemotherapy plus regional hyperthermia in high-grade soft tissue sarcomas: a retrospective comparison.
Zschaeck S; Wust P; Melcher I; Nadobny J; Rau D; Striefler J; Pahl S; Flörcken A; Kunitz A; Ghadjar P
Int J Hyperthermia; 2018; 35(1):1-9. PubMed ID: 30300018
[TBL] [Abstract][Full Text] [Related]
33. Tumor-Infiltrating PD-1+ Immune Cell Density is Associated with Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.
Kitagawa Y; Akiyoshi T; Yamamoto N; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Fukunaga Y; Hirota T; Noda T; Kawachi H
Clin Colorectal Cancer; 2022 Mar; 21(1):e1-e11. PubMed ID: 35123891
[TBL] [Abstract][Full Text] [Related]
34. [Results of isolated hyperthermic extremity perfusion in soft tissue sarcomas within the scope of a multimodality treatment concept].
Schwarzbach M; Lehnert T; Willeke F; Hinz U; Herfarth C
Chirurg; 1996 Dec; 67(12):1237-43. PubMed ID: 9081786
[TBL] [Abstract][Full Text] [Related]
35. Chemoradiotherapy plus hyperthermia (CRTH) versus chemoradiotherapy (CRT) alone in neoadjuvant treatment of soft tissue sarcoma: tumor response, treatment toxicity and disease control.
Willner A; Agaimy A; Fechner K; Ott O; Denz A; Weissmann T; Meidenbauer N; Höfler D; Gaipl U; Frey B; Schmidt M; Haller F; Horch R; Hartmann A; Grützmann R; Fietkau R; Semrau S
Int J Hyperthermia; 2023; 40(1):2248424. PubMed ID: 37611915
[TBL] [Abstract][Full Text] [Related]
36. Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis.
Perry LM; Cruz SM; Kleber KT; Judge SJ; Darrow MA; Jones LB; Basmaci UN; Joshi N; Settles ML; Durbin-Johnson BP; Gingrich AA; Monjazeb AM; Carr-Ascher J; Thorpe SW; Murphy WJ; Eisen JA; Canter RJ
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36599469
[TBL] [Abstract][Full Text] [Related]
37. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
38. Long-Term Follow-Up of Patients Receiving Neoadjuvant Treatment Modalties for Soft Tissue Sarcomas of the Extremities.
Rauch M; Agaimy A; Semrau S; Willner A; Ott O; Fietkau R; Hohenberger W; Croner RS; Grützmann R; Fechner K; Vassos N
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680391
[TBL] [Abstract][Full Text] [Related]
39. LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival.
Que Y; Fang Z; Guan Y; Xiao W; Xu B; Zhao J; Chen H; Zhang X; Zeng M; Liang Y; Zhang X
Cancer Biol Med; 2019 May; 16(2):331-340. PubMed ID: 31516753
[TBL] [Abstract][Full Text] [Related]
40. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
de Groot AF; Blok EJ; Charehbili A; Engels CC; Smit VTHBM; Dekker-Ensink NG; Putter H; Meershoek-Klein Kranenbarg E; van de Velde CJH; Liefers GJ; Nortier JWR; Kuppen PJK; van der Burg SH; Kroep JR
Breast Cancer Res Treat; 2019 Jun; 175(3):605-615. PubMed ID: 30868392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
